Trade bill may weaken domestic medical manufacturing while cutting tariffs

What it does

This bill authorizes the President to negotiate and enter into trade agreements with countries that meet certain criteria (rule of law, IP protection, open trade during health emergencies, etc.) to reduce or eliminate tariffs and trade barriers on medical goods. Congress gets 30–90 days to review and disapprove each agreement before it takes effect. The goal is to diversify U.S. medical supply sources and strengthen supply chains for future pandemics.

Why we flagged it

The bill's core mechanism is a delegation of trade-negotiation authority to the President with a congressional review-and-disapproval process. It is not a direct tariff cut or subsidy; it is a procedural grant of power to negotiate agreements that would then modify duties. The stated purpose is supply-chain resilience, but the operative effect is tariff reduction on medical imports.

What the text implies

• Tariff elimination on medical goods may reduce domestic manufacturing incentives and capacity, undermining the bill's stated goal of building U.S. supply resilience. Lower-cost imports could displace domestic producers, leaving the U.S. dependent on foreign suppliers during emergencies.
• The bill defines 'trusted trade partner' by agreement alone—a country becomes trusted once it signs the deal. This creates a circular definition: the President certifies a partner as trustworthy, then the partner's trustworthiness is defined by the agreement itself, with limited ex-ante vetting.
• Section 5(c)(10) exempts trusted partners from 'trade-restrictive measures imposed with respect to medical goods during a public health emergency.' This could prevent the U.S. from imposing export controls or tariffs on medical goods from these partners even if supply is threatened, paradoxically weakening emergency response tools.
• The 30–90 day congressional review window is tight for complex trade agreements affecting multiple sectors and countries. Congress may lack time to assess long-term supply-chain impacts or identify unintended consequences before agreements take effect.
• No explicit requirement that agreements prioritize domestic manufacturing capacity or investment. The bill emphasizes 'efficient' trade and 'most efficient and practicable' movement of goods, which may favor low-cost imports over domestic production.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens benefit from lower-cost medical goods and improved supply chain resilience in future pandemics. However, domestic medical manufacturers and workers in those sectors face increased competition from tariff-free imports, potentially reducing domestic production capacity and employment in medical manufacturing—the very capacity the bill claims to protect.

Who stands to gain

• foreign pharmaceutical manufacturers and suppliers
• foreign medical device manufacturers
• U.S. importers and distributors of medical goods
• U.S. consumers (lower prices on medical goods)

Named in the bill

President of the United States, United States Trade Representative, Senate Committee on Finance, House Committee on Ways and Means, Department of Health and Human Services, International Trade Commission, World Trade Organization, Agreement on Government Procurement

Where it stands

3 cosponsors: 2 Democrats, 1 Republicans.

• Mar 12, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 12, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

12 lobbying clients named this bill on 19 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $58,481,425 in lobbying spend. A filing names 14 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 93% of bills with at least one filing.

Thom Tillis, the sponsor, reported $973,475 in PAC receipts in the 2026 cycle. $5,000 of that came from 1 PAC tied to these lobbying clients.

• Chamber of Commerce of the U.S.A. — $54,660,000 on 3 filings
• UPS (united Parcel Service) — $1,500,000 on 1 filing
• Trinity Health — $720,000 on 3 filings
• Astrazeneca Pharmaceuticals Lp — $670,000 on 1 filing
• Vizient Inc — $320,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.